Natera, Inc. (NASDAQ:NTRA) Shares Purchased by Entropy Technologies LP

Entropy Technologies LP boosted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 35.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,634 shares of the medical research company’s stock after buying an additional 3,600 shares during the period. Entropy Technologies LP’s holdings in Natera were worth $1,731,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Apollon Wealth Management LLC acquired a new stake in shares of Natera during the 3rd quarter worth approximately $270,000. Jag Capital Management LLC increased its stake in Natera by 8.8% during the third quarter. Jag Capital Management LLC now owns 175,590 shares of the medical research company’s stock worth $22,291,000 after acquiring an additional 14,159 shares during the last quarter. GDS Wealth Management purchased a new stake in Natera in the third quarter valued at $459,000. Chartwell Investment Partners LLC lifted its stake in shares of Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after purchasing an additional 11,362 shares during the last quarter. Finally, Baker Avenue Asset Management LP purchased a new position in shares of Natera during the 3rd quarter worth $230,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on NTRA shares. Stephens reaffirmed an “overweight” rating and issued a $125.00 target price on shares of Natera in a research report on Friday, August 9th. Sanford C. Bernstein increased their price objective on shares of Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Robert W. Baird lifted their target price on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, August 9th. UBS Group decreased their price target on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, The Goldman Sachs Group boosted their price objective on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average target price of $125.69.

Natera Stock Performance

NASDAQ NTRA opened at $135.12 on Wednesday. Natera, Inc. has a 52 week low of $46.96 and a 52 week high of $140.00. The firm has a 50 day moving average of $125.09 and a two-hundred day moving average of $114.52. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,523 shares of Natera stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the sale, the chief executive officer now directly owns 191,163 shares of the company’s stock, valued at $24,927,655.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Steven Leonard Chapman sold 4,523 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the sale, the chief executive officer now owns 191,163 shares in the company, valued at approximately $24,927,655.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Solomon Moshkevich sold 1,196 shares of the stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.16. Following the completion of the transaction, the insider now directly owns 110,695 shares in the company, valued at $13,085,255.95. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,464 shares of company stock valued at $5,849,977 over the last quarter. 7.60% of the stock is owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.